HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma

por Lin, Shi-Ming, Lu, Sheng-Nan, Chen, Ping-Tsung, Jeng, Long-Bin, Chen, Shinn-Cherng, Hu, Chi-Tan, Yang, Sien-Sing, Le Berre, Marie-Aude, Liu, Xuan, Mitchell, David Y., Prins, Klaas, Grevel, Joachim, Peña, Carol A. E., Meinhardt, Gerold
Publicado 2016